Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

76.35 +0.55 (+0.73%)
Official Closing Price Updated: 4:15 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,651,015
Open 76.47
Bid (Size) 76.27 (7)
Ask (Size) 76.64 (15)
Prev. Close 75.80
Today's Range 75.43 - 76.49
52wk Range 60.47 - 76.80
Shares Outstanding N/A
Dividend Yield 1.22%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire

Performance

YTD
+11.62%
+11.62%
1 Month
+13.96%
+13.96%
3 Month
+14.21%
+14.21%
6 Month
+18.96%
+18.96%
1 Year
+2.36%
+2.36%

More News

Read More
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
From AstraZeneca
Via Business Wire
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
Via Chartmill
AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Double Good News For AstraZeneca's Breast Cancer Drugs
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
From AstraZeneca
Via Business Wire
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
Via Talk Markets
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Via Investor's Business Daily
Top 4 Health Care Stocks That May Plunge This Month
Via Benzinga
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
Via Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
Via Investor's Business Daily
Q1 2024 results
From AstraZeneca
Via Business Wire
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
European Stock: AstraZeneca
Via Talk Markets
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.